Evidence map›Paper›PMID 20428110›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Celia J A Morgan, Tom P Freeman, Gráinne L Schafer, H Valerie Curran

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. A randomised controlled trial of vaporised ΔEuropean archives of psychiatry and clinical neuroscience · 2019
    Trial
  13. Trial
  14. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  15. Trial
  16. Marijuana's acute effects on cognitive bias for affective and marijuana cues.Experimental and clinical psychopharmacology · 2015
    Trial
  17. Trial
  18. Trial
  19. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011
    Trial
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Celia J A MorganClinical Psychopharmacology Unit, Research Department of Clinical, Health and Educational Psychology, University College London, London, UK. c.morgan@ucl.ac.uk
Tom P Freeman
Gráinne L Schafer
H Valerie Curran
University College London · GBHealth Education England · GB

Funding

Medical Research Council G0800268Medical Research Council G0800268(85750)
6 · The paper itself

Abstract

Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabinoids have opposing effects both pharmacologically and behaviorally when administered in the laboratory. No research has yet examined how the ratio of these constituents impacts on the appetitive/reinforcing effects of cannabis in humans. A total of 94 cannabis users were tested 7 days apart, once while non-intoxicated and once while acutely under the influence of their own chosen smoked cannabis on dependence-related measures. Using an unprecedented methodology, a sample of cannabis (as well as saliva) was collected from each user and analyzed for levels of cannabinoids. On the basis of CBD : THC ratios in the cannabis, individuals from the top and bottom tertiles were directly compared on indices of the reinforcing effects of drugs, explicit liking, and implicit attentional bias to drug stimuli. When intoxicated, smokers of high CBD : THC strains showed reduced attentional bias to drug and food stimuli compared with smokers of low CBD : THC. Those smoking higher CBD : THC strains also showed lower self-rated liking of cannabis stimuli on both test days. Our findings suggest that CBD has potential as a treatment for cannabis dependence. The acute modulation of the incentive salience of drug cues by CBD may possibly generalize to a treatment for other addictive disorders.

Indexed as

AdolescentAnalysis of VarianceAppetitive BehaviorCannabidiolChoice BehaviorChromatography, LiquidDronabinolFemaleHallucinogensHumansMaleMarijuana AbuseMarijuana SmokingMass SpectrometryNeuropsychological TestsReaction TimeCannabidiolDronabinolHallucinogens

Identifiers

PMID20428110
PMCPMC2906701
OpenAlexW1972435539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.